New investigational drug holds promise for combatting deadly mucormycosis infections

February 6, 2014

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

An LA BioMed research team reported in an online, ahead-of-print study in the Antimicrobial Agents and Chemotherapy journal that the investigational drug isavuconazole was as effective in reducing mucormycosis infections in disease models as the most widely used treatment currently on the market, high-dose liposomal amphotericin B. Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of severe invasive and life-threatening . It is currently in phase 3 of clinical development.

"Expanding the options for fighting these is especially important for patients who can't tolerate current treatments or whose infections may not respond to the antifungals on the market today," said Ashraf S. Ibrahim, PhD, an LA BioMed lead researcher and the corresponding author for the study. "With such a limited number of treatments available, developing new therapies is critical to increasing the number of people who survive these extremely lethal infections. "

Patients with , hyperglycemia, acidosis (diabetic ketoacidosis or other forms of acidosis), malnutrition, or trauma patients are at increased risk of mucormycosis infection. Despite the current treatments and surgeries available to treat mucormycosis, more than half of patients with the infections die.

"Clearly, new strategies for preventing and treating mucormycosis are urgently needed," the researchers concluded.

They examined the most common form of this deadly infection, mucormycosis due to Rhizopus delemar, and concluded that their results support the further development of isavuconazole.

Related Stories

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.